Several studies have illustrated that some omics markers within tumors could impact patients’ survival, like the status of Isocitrate dehydrogenase 1/2 (IDH1/2) mutation, glioma-CpG island methylator phenotype (G-CIMP), methylation of O-6-methylguanine-DNA methyltransferase (MGMT), and codeletion for chromosome 1p and 19q (1p/19q codeletion) (Hartmann et al., 2010; Wick et al., 2013; Hainfellner et al., 2014; Louis et al., 2016). The gene discussed is MGMT; the disease is central nervous system cancer.